ApprovedFDA approval

Lynavoy (linerixibat)

Intercept Pharmaceuticals

Marketer take

Targets cholestatic itch in primary biliary cholangitis, a symptom-focused niche next to disease-modifying drugs like Iqirvo and Livdelzi, so hepatologists and gastroenterologists will hear quality-of-life messaging.

Sponsor company
Intercept Pharmaceuticals
Indication
To treat cholestatic pruritus associated with primary biliary cholangitis
Therapeutic area
Hepatology
Event
FDA approval
Date
Mar 17, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move